Report
← Signal Board

Cyclerion Therapeutics financial statements

사이클러리언 테라퓨틱스NASDAQ:CYCN · Nasdaq · Healthcare
$3.36+0.00%
2026-09-10 close

Cyclerion Therapeutics's published financial data is dated 2026-10-04. 2024 revenue was $2M. 2024 operating profit was −$3M.

Reported results

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -78.15
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-78.15
Beneish M-Score
—

Statistical flag unavailable

Sloan accrual
13.33%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

5/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score5/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -217%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 229% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-163.2%
Interest coverage
-15.7x
Return on equity (ROE)
-34.5%

Operating margin −5pp

Operating loss
Interest coverageBase -15.7x adverse case -16.2x
Return on equity (ROE)Base -34.5% adverse case -40.4%

Revenue −15%

Interest coverage risk
Interest coverageBase -15.7x adverse case -13.3x
Return on equity (ROE)Base -34.5% adverse case -33.7%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -15.7x adverse case -14.7x
Return on equity (ROE)Base -34.5% adverse case -39.4%

Interest coverage limit

Already below the limit by 173.7pp

Interest coverage limit at an operating margin of 10.4%

Interest expense coverage threshold

Cyclerion Therapeutics notifications

Quantus Signal · live data · not investment advice · Privacy Policy